Association Between Smoking Cessation and the Risk of Cholangiocarcinoma and Ampulla of Vater Cancer: A Nationwide Cohort Study
Introduction: The association between smoking cessation and intrahepatic and extrahepatic cholangiocarcinoma (iCCA and eCCA) risk is unclear. Furthermore, the association in individuals with preexisting risk factors is unknown. We aimed to investigate the association between smoking status (especially smoking cessation) and CCA risk according to individuals ’ glycemic status. Methods: In this nationwide cohort study, 9,520,629 adults without cancer who underwent national health screening by the Korean National Health Insurance Service in 2009 were followed up through 2018. The hazard ratios (HRs) and 95% confidence inter...
Source: Liver Cancer - February 9, 2023 Category: Cancer & Oncology Source Type: research

Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study
Conclusion: The achievement of CR rate by curative conversion in patients treated with atezolizumab plus bevacizumab as the preceding therapy for unresectable and TACE-unsuitable intermediate-stage HCC was 35%. Overall, 23% of patients achieved drug-free status and no recurrence was observed from this patient subgroup with CR and drug free status. Thus, achieving CR and/or drug-free status should be a therapeutic goal for patients with intermediate-stage HCC without vascular invasion or extrahepatic spread. (Source: Liver Cancer)
Source: Liver Cancer - February 7, 2023 Category: Cancer & Oncology Source Type: research

Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Hepatocellular Carcinoma ≤5 cm: Biological Characteristics and Patient Outcomes
Conclusions: Biological characteristics of HCC, including differentiation and level of Ki-67 expression, could influence major features of CEUS and impact the CEUS LI-RADS category. HCCs in different CEUS LI-RADS categories showed no significant differences in RFS after resection. (Source: Liver Cancer)
Source: Liver Cancer - January 24, 2023 Category: Cancer & Oncology Source Type: research

Contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) in hepatocellular carcinoma ≤ 5cm: biological characteristics and patient outcomes
This study revealed significant differences in the CEUS LI-RADS category of HCCs among differentiation (p (Source: Liver Cancer)
Source: Liver Cancer - January 24, 2023 Category: Cancer & Oncology Source Type: research

Optimizing survival benefit by surgical resection by the seven-eleven criteria in Barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the Milan criteria
Introduction: Optimal treatment of hepatocellular carcinoma (HCC) beyond the Milan criteria is in debate. We aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC) –A/B HCC beyond the Milan criteria with survival benefit. Methods: Patients with BCLC-A/B HCC beyond the Milan criteria at the National Taiwan University Hospital during 2005 and 2019 were screened and those who received transarterial chemoembolization (TACE) or SR were consecutively included. Th e tumor burden was classified by the seven-eleven criteria into low (≤7), intermediate (7-11) or high (>11). Multivariab...
Source: Liver Cancer - January 19, 2023 Category: Cancer & Oncology Source Type: research

Efficacy of Local Treatment in Lymph Node Metastasis from Hepatocellular Carcinoma
Conclusions: Our findings demonstrated the clinical significance of lymph node metastasis from hepatocellular carcinoma, which was well discriminated according to location, favoring regional metastasis. In patients with hepatocellular carcinoma presenting lymph node metastasis, active application of local treatment for lymph node metastasis can improve oncologic outcomes. (Source: Liver Cancer)
Source: Liver Cancer - January 18, 2023 Category: Cancer & Oncology Source Type: research

Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review
Conclusion This review supports liver function as a prognostic variable in aHCC, and highlights the value of a priori stratification of patients by baseline liver function in aHCC trials. The predic tive value of liver function warrants further study. Findings were limited by the quality of available data. (Source: Liver Cancer)
Source: Liver Cancer - January 17, 2023 Category: Cancer & Oncology Source Type: research

Long-term regression after discontinuation of regorafenib administered for sorafenib-refractory hepatocellular carcinoma
We present the potential of regorafenib effect for anti-tumor immunity through possible pharmacological mechanisms. (Source: Liver Cancer)
Source: Liver Cancer - January 16, 2023 Category: Cancer & Oncology Source Type: research

The 12th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2022)
naLiver Cancer 2022;11(suppl 1):1 –56 (Source: Liver Cancer)
Source: Liver Cancer - January 12, 2023 Category: Cancer & Oncology Source Type: research

Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
NA (Source: Liver Cancer)
Source: Liver Cancer - January 6, 2023 Category: Cancer & Oncology Source Type: research

Antibiotics associated with lower survival in hepatocellular cancer patients receiving immune checkpoint inhibitors independent of tumor status
not applicable (Source: Liver Cancer)
Source: Liver Cancer - December 29, 2022 Category: Cancer & Oncology Source Type: research

Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-analysis
Introduction: To investigate the incidence and spectrum of adverse events in unresectable hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs) or ICI-based combinations. Methods: The study protocol was prospectively registered on PROSPERO (CRD42022319255). We searched PubMed, EMBASE, and the Cochrane Library for published clinical trials from database inception to April 22, 2022. Studies that included at least one group of unresectable HCC patients treated with ICIs or ICI-based combinations and reported the incidence or spectrum of treatment-related adverse events (trAEs) or immune-rel...
Source: Liver Cancer - December 29, 2022 Category: Cancer & Oncology Source Type: research

Elderly Patients with Hepatocellular Carcinoma benefit from Liver Transplantation as much as younger ones
Abstract: Introduction: The literature on liver transplantation (LT) for cirrhosis-associated hepatocellular carcinoma (cirr-HCC) in elderly patients ( ≥65 years of age) is scarce. The aim of this study was therefore to analyze the outcome after LT for cirr-HCC in elderly patients in our single-center experience. Methods: All consecutive patients who underwent LT for cirr-HCC at our center were identified from our prospectively collected LT datab ase and stratified into an elderly (≥65 years) and a younger ( (Source: Liver Cancer)
Source: Liver Cancer - December 26, 2022 Category: Cancer & Oncology Source Type: research

Surgical resection or radiofrequency ablation for small hepatocellular carcinoma
not required (Source: Liver Cancer)
Source: Liver Cancer - December 23, 2022 Category: Cancer & Oncology Source Type: research

Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients – multicenter analysis
This study aimed to elucidate the clinical relationship between MVL and Atez/Bev. Materials/Methods: From September 2020 to December 2021, 229 u-HCC patients treated with Atez/Bev and with muscle volume data obtained by computed tomography at the baseline available were analyzed (median age, 74 years; males, 186 (81.2%); ECOG PS 0/1, 221 (96.5%); HCV:HBV:alcohol:others=81:33:40:75; Child-Pugh A, 212 (92.6%); mALBI grade 1:2a:2b=79:60:90; BCLC 0:A:B:C =1:24:87:117; median observation period, 6.8 months). Japan Society of Hepatology criteria were used for definition of MVL and prognostic factors were retrospectively evaluat...
Source: Liver Cancer - December 8, 2022 Category: Cancer & Oncology Source Type: research